EVE Health Group Limited (ASX:EVE)

EVE Health Group Limited, an Australian life sciences company, has announced the appointment of its first dedicated Medical Science Liaison (MSL) to lead national medical education and engagement programs. This move expands EVE's medical capabilities, particularly following the launch of its Dyspro™ and the upcoming launch of Libbo™ formulations, which aim to address women's and men's health issues. The MSL will play a crucial role in educating and engaging with healthcare professionals across Australia, supporting the clinical adoption of these products. The MSL will also focus on communicating the clinical benefits, facilitating training sessions, and ensuring prescribers have access to the latest product data and patient outcomes. This appointment marks a significant step in EVE's commercial rollout strategy and underscores its commitment to building confidence among prescribers and expanding patient access.